Carbocaine

(Mepivacaine Hydrochloride)

PreclinicalSmall molecule

Pfizer

Carbocaine is one of 5 small molecule programs targeting Pain Perception. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Pain PerceptionUnknown status

Pain PerceptionPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Pain Perception

#DrugCompanyPhaseTrials

Advil

KKenvue Brands

Approved

2 2

Tylenol

KKenvue Brands

Approved

1 3

Yohimbine

NNational Institute of Mental Health (NIMH)

Preclinical

1 4

Carbocaine

Pfizer

Preclinical

1 5

Buffer

NNorthwestern University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pain Perception1 trial

Effect of Different Approaches of Delivering Local Dental Anesthesia on Pain Perception in Children.

Unknown status·MMansoura University·N/A·NCT05338983·80 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

CARBOCAINE

NDA NDA012125

Jan 1, 1982

CARBOCAINE

NDA NDA012250

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mepivacaine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mepivacaine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mepivacaine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA012125). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Carbocaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pain Perception1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News